Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""TUMOR lysis syndrome"" wg kryterium: Temat


Tytuł :
Spontaneous tumour lysis syndrome in multiple myeloma with loss of 17p13.1, t(4;14) and monosomy 13.
Autorzy :
Tbakhi B; Hematology/Oncology, University of Rochester, Rochester, New York, USA .
Hanna S; Internal Medicine, Unity Hospital, Rochester, New York, USA.
Samhouri Y; Hematology/Oncology, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA.
Lingutla D; Internal Medicine, Unity Hospital, Rochester, New York, USA.
Pokaż więcej
Źródło :
BMJ case reports [BMJ Case Rep] 2021 Feb 05; Vol. 14 (2). Date of Electronic Publication: 2021 Feb 05.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Multiple Myeloma/*complications
Tumor Lysis Syndrome/*genetics
Diagnosis, Differential ; Drug Therapy, Combination ; Fatal Outcome ; Humans ; Male ; Middle Aged ; Monosomy ; Multiple Myeloma/diagnosis ; Multiple Myeloma/therapy ; Renal Dialysis ; Tumor Lysis Syndrome/diagnosis ; Tumor Lysis Syndrome/therapy
Czasopismo naukowe
Tytuł :
Tumor lysis syndrome: still the Achilles heel of venetoclax in treatment of CLL?
Autorzy :
Anderson MA; Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia.; Division of Blood Cells and Blood Cancer, The Walter and Eliza Hall Institute, Parkville, Australia.
Seymour JF; Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia.; Department of Medicine Dentistry and Health Sciences, The University of Melbourne, Parkville, Australia.
Pokaż więcej
Źródło :
Leukemia & lymphoma [Leuk Lymphoma] 2020 Oct; Vol. 61 (10), pp. 2286-2288. Date of Electronic Publication: 2020 Aug 04.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Tumor Lysis Syndrome*/diagnosis
Tumor Lysis Syndrome*/epidemiology
Tumor Lysis Syndrome*/etiology
Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Humans ; Incidence ; Patients ; Sulfonamides
Czasopismo naukowe
Tytuł :
[Recommendations for tumor lysis syndrome management].
Transliterated Title :
Recomendaciones para el manejo de la lisis tumoral.
Corporate Authors :
Comité Nacional de Hematología, Oncología y Medicina Transfusional
Źródło :
Archivos argentinos de pediatria [Arch Argent Pediatr] 2020 Apr; Vol. 118 (2), pp. S59-S63.
Typ publikacji :
Journal Article; Practice Guideline
MeSH Terms :
Tumor Lysis Syndrome/*diagnosis
Tumor Lysis Syndrome/*therapy
Combined Modality Therapy ; Humans ; Risk Factors ; Tumor Lysis Syndrome/etiology ; Tumor Lysis Syndrome/physiopathology
Czasopismo naukowe
Tytuł :
Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia.
Autorzy :
Cheng FM; Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, 2 Yude Rd, North District, Taichung, 404, Taiwan.
Tien JZ; Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, 2 Yude Rd, North District, Taichung, 404, Taiwan.
Chen TT; Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, 2 Yude Rd, North District, Taichung, 404, Taiwan.
Yeh SP; Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, 2 Yude Rd, North District, Taichung, 404, Taiwan.
Lin CC; Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, 2 Yude Rd, North District, Taichung, 404, Taiwan. .; Graduate Institute of Clinical Medical Science, China Medical University, Taichung, 404, Taiwan. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Sep; Vol. 99 (9), pp. 2193-2195. Date of Electronic Publication: 2020 Jul 03.
Typ publikacji :
Letter
MeSH Terms :
Bridged Bicyclo Compounds, Heterocyclic/*administration & dosage
Cytochrome P-450 Enzyme Inhibitors/*administration & dosage
Leukemia, Myeloid, Acute/*drug therapy
Sulfonamides/*administration & dosage
Tumor Lysis Syndrome/*prevention & control
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Azacitidine/administration & dosage ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Bridged Bicyclo Compounds, Heterocyclic/pharmacokinetics ; Child ; Creatinine/blood ; Cytochrome P-450 Enzyme Inhibitors/adverse effects ; Cytochrome P-450 Enzyme Inhibitors/pharmacokinetics ; Drug Administration Schedule ; Drug Synergism ; Female ; Humans ; Hyperuricemia/chemically induced ; Hyperuricemia/drug therapy ; Leukemia, Myeloid, Acute/blood ; Male ; Middle Aged ; Retrospective Studies ; Sulfonamides/adverse effects ; Sulfonamides/pharmacokinetics ; Triazoles/administration & dosage ; Triazoles/adverse effects ; Triazoles/pharmacokinetics ; Tumor Lysis Syndrome/etiology ; Urate Oxidase/therapeutic use ; Uric Acid/blood ; Young Adult
Opinia redakcyjna
Tytuł :
Tumor Lysis Syndrome After Laparoscopic Microwave Ablation of Colorectal Liver Metastases.
Autorzy :
Sheka AC; Department of Surgery, University of Minnesota, MMC 195, 420 Delaware St. SE, Minneapolis, MN, 55455, USA.
Altman A; Department of Surgery, University of Minnesota, MMC 195, 420 Delaware St. SE, Minneapolis, MN, 55455, USA.
Gasparetto A; Department of Radiology, University of Minnesota, Minneapolis, MN, USA.
Spilseth B; Department of Radiology, University of Minnesota, Minneapolis, MN, USA.
Muratore S; Department of Surgery, University of Minnesota, MMC 195, 420 Delaware St. SE, Minneapolis, MN, 55455, USA.
Jensen EH; Department of Surgery, University of Minnesota, MMC 195, 420 Delaware St. SE, Minneapolis, MN, 55455, USA. .
Pokaż więcej
Źródło :
Journal of gastrointestinal cancer [J Gastrointest Cancer] 2020 Jun; Vol. 51 (2), pp. 631-635.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Catheter Ablation/*adverse effects
Colorectal Neoplasms/*surgery
Laparoscopy/*adverse effects
Liver Neoplasms/*surgery
Microwaves/*adverse effects
Tumor Lysis Syndrome/*pathology
Colorectal Neoplasms/pathology ; Female ; Humans ; Liver Neoplasms/secondary ; Middle Aged ; Prognosis ; Tumor Lysis Syndrome/etiology
Czasopismo naukowe
Tytuł :
A retrospective analysis of tumor lysis syndrome management in a quaternary care hospital.
Autorzy :
Eng S; PGY1 Pharmacy Resident, Hackensack University Medical Center, Hackensack, USA.
Lee CS; Department of Clinical Health Professions, College of Pharmacy and Health Sciences, St. John's University, Queens, USA.; Division of Medical Oncology and Hematology Northwell Health Cancer Institute Donald & Barbara Zucker School of Medicine at Hofstra/Northwell Lake Success, NY.
Ahn S; Biostatistics Unit, Feinstein Institute for Medical Research, Manhasset, USA.
Sharma A; Division of Medical Oncology and Hematology Northwell Health Cancer Institute Donald & Barbara Zucker School of Medicine at Hofstra/Northwell Lake Success, NY.
Pokaż więcej
Źródło :
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2020 Mar; Vol. 26 (2), pp. 338-344. Date of Electronic Publication: 2019 May 14.
Typ publikacji :
Journal Article
MeSH Terms :
Disease Management*
Gout Suppressants/*administration & dosage
Quaternary Prevention/*methods
Tumor Lysis Syndrome/*drug therapy
Tumor Lysis Syndrome/*etiology
Urate Oxidase/*administration & dosage
Adult ; Aged ; Female ; Humans ; Hyperuricemia/diagnosis ; Hyperuricemia/drug therapy ; Male ; Middle Aged ; Post-Exposure Prophylaxis/methods ; Retrospective Studies ; Tumor Lysis Syndrome/diagnosis
Czasopismo naukowe
Tytuł :
Emergencies in haematology: tumour lysis syndrome.
Autorzy :
Durani U; Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Hogan WJ; Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2020 Feb; Vol. 188 (4), pp. 494-500. Date of Electronic Publication: 2019 Nov 27.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Fluid Therapy*
Tumor Lysis Syndrome*/blood
Tumor Lysis Syndrome*/mortality
Tumor Lysis Syndrome*/therapy
Allopurinol/*therapeutic use
Hematologic Neoplasms/blood ; Hematologic Neoplasms/mortality ; Hematologic Neoplasms/therapy ; Humans ; Risk Factors
Czasopismo naukowe
Tytuł :
Severe tumor lysis syndrome during the induction therapy for the treatment of blastic plasmacytoid dendritic cell neoplasm arising from myelodysplastic/myeloproliferative neoplasms.
Autorzy :
Sagou, Ken (AUTHOR)
Ito, Makoto (AUTHOR)
Kawamura, Yuma (AUTHOR)
Ukai, Shun (AUTHOR)
Goto, Miyo (AUTHOR)
Fukushima, Nobuaki (AUTHOR)
Ozeki, Kazutaka (AUTHOR)
Fukuyama, Ryuichi (AUTHOR)
Kohno, Akio (AUTHOR)
Pokaż więcej
Źródło :
Clinical Case Reports. Feb2021, Vol. 9 Issue 2, p878-882. 5p.
Czasopismo naukowe
Tytuł :
Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations.
Autorzy :
Tambaro FP; Dipartimento di Oncoematologia-Unità di trapianto di midollo osseo, UT MD Anderson Cancer Center, Houston, TX, USA; Azienda Ospedaliera di Rilievo Nazionale Santobono-Pausilipon, Napoli, Italy.
Wierda WG; Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX, USA. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2020 Feb; Vol. 7 (2), pp. e168-e176.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Agents/*adverse effects
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Molecular Targeted Therapy/*adverse effects
Neoplasm Proteins/*antagonists & inhibitors
Protein Kinase Inhibitors/*adverse effects
Proto-Oncogene Proteins c-bcl-2/*antagonists & inhibitors
Tumor Lysis Syndrome/*etiology
Acute Kidney Injury/etiology ; Acute Kidney Injury/therapy ; Allopurinol/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Arrhythmias, Cardiac/drug therapy ; Arrhythmias, Cardiac/etiology ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Drug Synergism ; Humans ; Hyperphosphatemia/etiology ; Hyperphosphatemia/therapy ; Hyperuricemia/drug therapy ; Hyperuricemia/etiology ; Leukemia, Lymphocytic, Chronic, B-Cell/enzymology ; Renal Dialysis ; Risk Factors ; Severity of Illness Index ; Sulfonamides/adverse effects ; Sulfonamides/therapeutic use ; Tumor Lysis Syndrome/diagnosis ; Tumor Lysis Syndrome/drug therapy ; Tumor Lysis Syndrome/prevention & control ; Urate Oxidase/therapeutic use
Czasopismo naukowe
Tytuł :
Tumor Lysis Syndrome.
Autorzy :
Russell TB; Section of Pediatric Hematology/Oncology, Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, NC.
Kram DE; Section of Pediatric Hematology/Oncology, Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, NC.
Pokaż więcej
Źródło :
Pediatrics in review [Pediatr Rev] 2020 Jan; Vol. 41 (1), pp. 20-26.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Tumor Lysis Syndrome*/diagnosis
Tumor Lysis Syndrome*/etiology
Tumor Lysis Syndrome*/therapy
Antineoplastic Agents/*adverse effects
Humans ; Leukocyte Count ; Risk Assessment ; Risk Factors
Czasopismo naukowe
Tytuł :
Venetoclax-induced tumour lysis syndrome in acute myeloid leukaemia.
Autorzy :
Esparza S; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Muluneh B; Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Galeotti J; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA.
Matson M; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Richardson DR; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.; The Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC, USA.
Montgomery ND; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA.
Coombs CC; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Jamieson K; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Foster MC; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Zeidner JF; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2020 Jan; Vol. 188 (1), pp. 173-177. Date of Electronic Publication: 2019 Oct 16.
Typ publikacji :
Case Reports; Letter
MeSH Terms :
Leukemia, Myeloid, Acute*/blood
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/pathology
Tumor Lysis Syndrome*/blood
Tumor Lysis Syndrome*/diagnosis
Tumor Lysis Syndrome*/pathology
Bridged Bicyclo Compounds, Heterocyclic/*adverse effects
Sulfonamides/*adverse effects
Aged ; Bridged Bicyclo Compounds, Heterocyclic/administration & dosage ; Humans ; Male ; Sulfonamides/administration & dosage
Raport
Tytuł :
Successful Intensive Care Treatment of Severe Lactic Acidosis and Tumor Lysis Syndrome Related to Intravascular Lymphoma.
Autorzy :
Mase H; Department of Anesthesiology, Nippon Medical School.; Department of Surgical Intensive Care, Nippon Medical School.
Ogawa Y; Department of Anesthesiology, Nippon Medical School.
Takeuchi J; Department of Anesthesiology, Nippon Medical School.
Genda Y; Department of Anesthesiology, Nippon Medical School.; Department of Surgical Intensive Care, Nippon Medical School.
Ichiba S; Department of Surgical Intensive Care, Nippon Medical School.
Sakamoto A; Department of Anesthesiology, Nippon Medical School.
Pokaż więcej
Źródło :
Journal of Nippon Medical School = Nippon Ika Daigaku zasshi [J Nippon Med Sch] 2020 Mar 11; Vol. 87 (1), pp. 32-36. Date of Electronic Publication: 2019 Jul 15.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Critical Care*
Lactic Acid*
Acidosis/*therapy
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Lymphoma, Large B-Cell, Diffuse/*complications
Tumor Lysis Syndrome/*etiology
Vascular Neoplasms/*complications
Acidosis/etiology ; Cyclophosphamide/administration & dosage ; Doxorubicin/administration & dosage ; Humans ; Male ; Middle Aged ; Multiple Organ Failure/etiology ; Prednisolone/administration & dosage ; Renal Replacement Therapy ; Rituximab/administration & dosage ; Severity of Illness Index ; Tumor Lysis Syndrome/therapy ; Vascular Neoplasms/therapy ; Vincristine/administration & dosage
Czasopismo naukowe
Tytuł :
Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia.
Autorzy :
Gribben JG; Barts Cancer Institute, St. Bartholomew's Hospital, Queen Mary University of London, London, UK.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2020 Mar; Vol. 188 (6), pp. 844-851. Date of Electronic Publication: 2019 Dec 19.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Bridged Bicyclo Compounds, Heterocyclic/*adverse effects
Leukemia, Lymphocytic, Chronic, B-Cell/*complications
Sulfonamides/*adverse effects
Tumor Lysis Syndrome/*etiology
Aged ; Antineoplastic Agents/pharmacology ; Bridged Bicyclo Compounds, Heterocyclic/pharmacology ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Male ; Middle Aged ; Sulfonamides/pharmacology ; Sulfonamides/therapeutic use ; Tumor Lysis Syndrome/drug therapy
Czasopismo naukowe
Tytuł :
Tumor lysis syndrome associated with bortezomib: A post-hoc analysis after signal detection using the US Food and Drug Administration Adverse Event Reporting System.
Autorzy :
Sanagawa A; Department of Pharmacy, Nagoya City University Hospital.; Departments of Hospital Pharmacy.
Hotta Y; Departments of Hospital Pharmacy.
Kondo M; Department of Pharmacy, Nagoya City University Hospital.
Nishikawa R; Regulatory Science, Graduate School of Pharmaceutical Sciences.
Tohkin M; Regulatory Science, Graduate School of Pharmaceutical Sciences.
Kimura K; Department of Pharmacy, Nagoya City University Hospital.; Departments of Hospital Pharmacy.; Department of Clinical Pharmaceutics, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Pokaż więcej
Źródło :
Anti-cancer drugs [Anticancer Drugs] 2020 Feb; Vol. 31 (2), pp. 183-189.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Adverse Drug Reaction Reporting Systems/*statistics & numerical data
Antineoplastic Agents/*adverse effects
Bortezomib/*adverse effects
Drug-Related Side Effects and Adverse Reactions/*diagnosis
Multiple Myeloma/*drug therapy
Tumor Lysis Syndrome/*diagnosis
Drug-Related Side Effects and Adverse Reactions/etiology ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Multiple Myeloma/pathology ; Prognosis ; Survival Rate ; Tumor Lysis Syndrome/etiology ; United States ; United States Food and Drug Administration
Czasopismo naukowe
Tytuł :
Carfilzomib-induced tumor lysis syndrome in relapsed multiple myeloma: a report of two cases.
Autorzy :
Terzi Demirsoy E; Department of Hematology, Kocaeli University School of Medicine, Kocaeli, Turkey.
Birtas Atesoglu E; Department of Hematology, Kocaeli University School of Medicine, Kocaeli, Turkey.
Eren N; Department of Nephrology, Kocaeli University School of Medicine, Kocaeli, Turkey.
Gedük A; Department of Hematology, Kocaeli University School of Medicine, Kocaeli, Turkey.
Mehtap O; Department of Hematology, Kocaeli University School of Medicine, Kocaeli, Turkey.
Tarkun P; Department of Hematology, Kocaeli University School of Medicine, Kocaeli, Turkey.
Hacıhanefioğlu A; Department of Hematology, Kocaeli University School of Medicine, Kocaeli, Turkey.
Pokaż więcej
Źródło :
Tumori [Tumori] 2019 Dec; Vol. 105 (6), pp. NP24-NP27. Date of Electronic Publication: 2018 Dec 23.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antineoplastic Agents/*adverse effects
Multiple Myeloma/*complications
Oligopeptides/*adverse effects
Tumor Lysis Syndrome/*diagnosis
Tumor Lysis Syndrome/*etiology
Aged ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers ; Fatal Outcome ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/diagnosis ; Multiple Myeloma/drug therapy ; Multiple Myeloma/genetics ; Oligopeptides/therapeutic use ; Positron Emission Tomography Computed Tomography ; Renal Dialysis ; Treatment Outcome ; Tumor Lysis Syndrome/therapy
Czasopismo naukowe
Tytuł :
Myocardial calcification in a patient with B-lymphoblastic leukemia accompanied by tumor lysis syndrome.
Autorzy :
Usui G; Department of Diagnostic Pathology, NTT Medical Center Tokyo, Tokyo, Japan.
Hashimoto H; Department of Diagnostic Pathology, NTT Medical Center Tokyo, Tokyo, Japan; Faculty of Healthcare, Tokyo Healthcare University, Tokyo, Japan. Electronic address: .
Uchibori Y; Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
Usuki K; Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
Horiuchi H; Department of Diagnostic Pathology, NTT Medical Center Tokyo, Tokyo, Japan.
Morikawa T; Department of Diagnostic Pathology, NTT Medical Center Tokyo, Tokyo, Japan; Faculty of Healthcare, Tokyo Healthcare University, Tokyo, Japan.
Pokaż więcej
Źródło :
Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology [Cardiovasc Pathol] 2019 Nov - Dec; Vol. 43, pp. 107146. Date of Electronic Publication: 2019 Aug 07.
Typ publikacji :
Case Reports
MeSH Terms :
Antineoplastic Agents/*adverse effects
Calcinosis/*etiology
Cardiomyopathies/*etiology
Myocardium/*pathology
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy
Prednisolone/*adverse effects
Tumor Lysis Syndrome/*etiology
Autopsy ; Biomarkers/blood ; Calcinosis/blood ; Calcinosis/pathology ; Cardiomyopathies/blood ; Cardiomyopathies/pathology ; Cause of Death ; Fatal Outcome ; Humans ; Male ; Middle Aged ; Myocardium/metabolism ; Phosphorus/blood ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Tumor Lysis Syndrome/blood ; Tumor Lysis Syndrome/pathology ; Up-Regulation
Raport
Tytuł :
Current understanding of tumor lysis syndrome.
Autorzy :
Rahmani B; Department of Physiology and Biophysics, Stony Brook University Renaissance School of Medicine, Stony Brook, New York.
Patel S; Department of Physiology and Biophysics, Stony Brook University Renaissance School of Medicine, Stony Brook, New York.
Seyam O; Department of Physiology and Biophysics, Stony Brook University Renaissance School of Medicine, Stony Brook, New York.
Gandhi J; Department of Physiology and Biophysics, Stony Brook University Renaissance School of Medicine, Stony Brook, New York.; Medical Student Research Institute, St. George's University School of Medicine, Grenada, West Indies, Grenada.
Reid I; Department of Physiology and Biophysics, Stony Brook University Renaissance School of Medicine, Stony Brook, New York.
Smith N; Foley Plaza Medical, New York, New York.
Khan SA; Department of Physiology and Biophysics, Stony Brook University Renaissance School of Medicine, Stony Brook, New York.; Department of Urology, Stony Brook University Renaissance School of Medicine, Stony Brook, New York.
Pokaż więcej
Źródło :
Hematological oncology [Hematol Oncol] 2019 Dec; Vol. 37 (5), pp. 537-547. Date of Electronic Publication: 2019 Sep 11.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Tumor Lysis Syndrome/*etiology
Animals ; Biomarkers ; Humans ; Neoplasms/complications ; Neoplasms/therapy ; Radiography ; Risk Assessment ; Risk Factors ; Severity of Illness Index ; Symptom Assessment ; Tumor Lysis Syndrome/diagnosis
Czasopismo naukowe
Tytuł :
Understanding tumor lysis syndrome.
Autorzy :
Zafrani L; Medical Intensive Care Unit, Hopital Saint Louis, Assistance des Hôpitaux de Paris, Paris University, Paris, France. .; INSERM, UMR 976, Human Immunology Pathophysiology and Immunotherapy, Hôpital Saint Louis, Paris, France. .
Canet E; Intensive Care Unit, Nantes University Hospital, Nantes, France.
Darmon M; Medical Intensive Care Unit, Hopital Saint Louis, Assistance des Hôpitaux de Paris, Paris University, Paris, France.
Pokaż więcej
Źródło :
Intensive care medicine [Intensive Care Med] 2019 Nov; Vol. 45 (11), pp. 1608-1611. Date of Electronic Publication: 2019 Sep 13.
Typ publikacji :
Journal Article
MeSH Terms :
Tumor Lysis Syndrome/*complications
Tumor Lysis Syndrome/*etiology
Drug Therapy/methods ; Humans ; Neoplasms/drug therapy ; Nephrocalcinosis/prevention & control ; Renal Replacement Therapy/methods ; Tumor Lysis Syndrome/physiopathology
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies